GSK Faculty

People

  1. Diehl
    Diehl
  2. Bromberg
    Bromberg
  3. Jiang
    Jiang
  4. Chaudhuri
    Chaudhuri
  5. Sun
    Sun
  6. Farese
    Farese
  7. Tammela
    Tammela
  8. Luo
    Luo
  9. Li
    Li
  10. Wendel
    Wendel
  11. Ganesh
    Ganesh
  12. Jasin
    Jasin
  13. Nikolov
    Nikolov
  14. Thompson
    Thompson
  15. Cheng
    Cheng

Description

Publications

  1. Blood (1359)
  2. Journal of Clinical Oncology (1161)
  3. Cancer Research (1091)
  4. Clinical Cancer Research (490)
  5. Modern Pathology (479)
  6. Journal of Nuclear Medicine (452)
  7. Journal of Biological Chemistry (427)
  8. Laboratory Investigation (413)
  9. Proceedings of the National Academy of Sciences of the United States of America (388)
  10. International Journal of Radiation Oncology, Biology, Physics (380)

Publishers

  1. Nature Publishing Group (2229)
  2. Elsevier Inc. (1816)
  3. American Association for Cancer Research (1572)
  4. American Society of Hematology (1417)
  5. Cell Press (1301)
  6. American Society of Clinical Oncology (1223)
  7. Oxford University Press (662)
  8. Springer (620)
  9. Wiley Blackwell (614)
  10. Elsevier Science, Inc. (535)

Sub-Groups

Types of Work

Recent Works

  1. A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Rosenbaum, E.; Gularte MeĢrida, R.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  2. A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  3. INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations
    Meeting Abstract

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Achour, H.; Sherman, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save